- Home
- BPOP vs IONS Comparison
BPOP vs IONS Comparison
Compare BPOP & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPOP
- IONS
- Stock Information
- Founded
- BPOP 1893
- IONS 1989
- Country
- BPOP United States
- IONS United States
- Employees
- BPOP N/A
- IONS N/A
- Industry
- BPOP Major Banks
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- BPOP Finance
- IONS Health Care
- Exchange
- BPOP Nasdaq
- IONS Nasdaq
- Market Cap
- BPOP 7.8B
- IONS 6.8B
- IPO Year
- BPOP N/A
- IONS 1991
- Fundamental
- Price
- BPOP $125.16
- IONS $61.17
- Analyst Decision
- BPOP Buy
- IONS Buy
- Analyst Count
- BPOP 7
- IONS 17
- Target Price
- BPOP $127.29
- IONS $67.88
- AVG Volume (30 Days)
- BPOP 563.3K
- IONS 3.3M
- Earning Date
- BPOP 10-22-2025
- IONS 11-05-2025
- Dividend Yield
- BPOP 2.37%
- IONS N/A
- EPS Growth
- BPOP 44.82
- IONS N/A
- EPS
- BPOP 10.29
- IONS N/A
- Revenue
- BPOP $2,799,129,000.00
- IONS $944,050,000.00
- Revenue This Year
- BPOP $0.07
- IONS $24.30
- Revenue Next Year
- BPOP $7.45
- IONS $6.50
- P/E Ratio
- BPOP $12.32
- IONS N/A
- Revenue Growth
- BPOP 8.02
- IONS 16.05
- 52 Week Low
- BPOP $78.23
- IONS $23.95
- 52 Week High
- BPOP $128.66
- IONS $64.72
- Technical
- Relative Strength Index (RSI)
- BPOP 62.35
- IONS 71.80
- Support Level
- BPOP $121.63
- IONS $60.64
- Resistance Level
- BPOP $124.90
- IONS $64.61
- Average True Range (ATR)
- BPOP 2.00
- IONS 2.41
- MACD
- BPOP -0.46
- IONS 0.35
- Stochastic Oscillator
- BPOP 50.21
- IONS 84.29
About BPOP Popular Inc.
Popular Inc, based in Puerto Rico, is a financial holding company with four main subsidiaries: Banco Popular de Puerto Rico, a bank in Puerto Rico in terms of assets; Banco Popular North America, its banking operation in the continental United States; Evertec, a data processor; and Popular Financial Holdings, a diversified financial services company. The Corporation's reportable segments consist of Banco Popular de Puerto Rico and Popular U.S.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.